TY  - JOUR
A1  - Schatton, Tobias
A1  - Yang, Jun
A1  - Kleffel, Sonja
A1  - Uehara, Mayuko
A1  - Barthel, Steven R.
A1  - Schlapbach, Christoph
A1  - Zhan, Qian
A1  - Dudeney, Stephen
A1  - Mueller, Hansgeorg
A1  - Lee, Nayoung
A1  - de Vries, Juliane C.
A1  - Meier, Barbara
A1  - Beken, Seppe Vander
A1  - Kluth, Mark A.
A1  - Ganss, Christoph
A1  - Sharpe, Arlene H.
A1  - Waaga-Gasser, Ana Maria
A1  - Sayegh, Mohamed H.
A1  - Abdi, Reza
A1  - Scharffetter-Kochanek, Karin
A1  - Murphy, George F.
A1  - Kupper, Thomas S.
A1  - Frank, Natasha Y.
A1  - Frank, Markus H.
T1  - ABCB5 Identifies Immunoregulatory Dermal Cells
JF  - Cell Reports
N2  - Cell-based strategies represent a new frontier in the treatment of immune-mediated disorders. However, the paucity of markers for isolation of molecularly defined immunomodulatory cell populations poses a barrier to this field. Here, we show that ATP-binding cassette member B5 (ABCB5) identifies dermal immunoregulatory cells (DIRCs) capable of exerting therapeutic immunoregulatory functions through engagement of programmed cell death 1 (PD-1). Purified Abcb5\(^+\) DIRCs suppressed T cell proliferation, evaded immune rejection, homed to recipient immune tissues, and induced Tregs in vivo. In fully major-histocompatibility-complex-mismatched cardiac allotransplantation models, allogeneic DIRCs significantly prolonged allograft survival. Blockade of DIRC-expressed PD-1 reversed the inhibitory effects of DIRCs on T cell activation, inhibited DIRC-dependent Treg induction, and attenuated DIRC-induced prolongation of cardiac allograft survival, indicating that DIRC immunoregulatory function is mediated, at least in part, through PD-1. Our results identify ABCB5\(^+\) DIRCs as a distinct immunoregulatory cell population and suggest promising roles of this expandable cell subset in cellular immunotherapy.
KW  - mesenchymal stem cells
KW  - P-glycoprotein
KW  - regulatory T cells
KW  - maintain immune homeostasis
KW  - malignant melanoma
KW  - in vivo
KW  - skin
KW  - generation
KW  - transplant
KW  - tolerance
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-149989
VL  - 12
SP  - 1564
EP  - 1574
ER  - 
TY  - JOUR
A1  - Tappenbeck, Nils
A1  - Schröder, Hannes M.
A1  - Niebergall-Roth, Elke
A1  - Hassinger, Fathema
A1  - Dehio, Ulf
A1  - Dieter, Kathrin
A1  - Kraft, Korinna
A1  - Kerstan, Andreas
A1  - Esterlechner, Jasmina
A1  - Frank, Natasha Y.
A1  - Scharffetter-Kochanek, Karin
A1  - Murphy, George F.
A1  - Orgill, Dennis P.
A1  - Beck, Joachim
A1  - Frank, Markus H.
A1  - Ganss, Christoph
A1  - Kluth, Mark A.
T1  - In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials
JF  - Cytotherapy
N2  - Background aims
Human dermal ABCB5-expressing mesenchymal stromal cells (ABCB5+ MSCs) represent a promising candidate for stem cell–based therapy of various currently uncurable diseases in several fields of regenerative medicine. We have developed and validated a method to isolate, from human skin samples, and expand ABCB5+ MSCs that meet the guideline criteria of the International Society for Cellular Therapy. We are able to process these cells into a Good Manufacturing Practice–conforming, MSC-based advanced-therapy medicinal product.

Methods
To support the development of ABCB5+ MSCs for potential therapeutic topical, intramuscular and intravenous administration, we have tested our product in a series of Good Laboratory Practice–compliant nonclinical in-vivo studies addressing all relevant aspects of biosafety, including potential long-term persistence and proliferation, distribution to nontarget tissues, differentiation into undesired cell types, ectopic tissue formation, tumor formation and local tissue reaction.

Results
(i) Subcutaneous application of 1 × 107 ABCB5+ MSCs/animal and intravenous application of 2 × 106 ABCB5+ MSCs/animal, respectively, to immunocompromised mice did not result in safety-relevant biodistribution, persistence or proliferation of the cells; (ii) three monthly subcutaneous injections of ABCB5+ MSCs at doses ranging from 1 × 105 to 1 × 107 cells/animal and three biweekly intravenous injections of 2 × 106 ABCB5+ MSCs/animal, respectively, to immunocompromised mice were nontoxic and revealed no tumorigenic potential; and (iii) intramuscular injection of 5 × 106 ABCB5+ MSCs/animal to immunocompromised mice was locally well tolerated.

Discussion
The present preclinical in vivo data demonstrate the local and systemic safety and tolerability of a novel advanced-therapy medicinal product based on human skin-derived ABCB5+ MSCs.
KW  - stromal cells
KW  - stem cells
KW  - MSC
KW  - biodistribution
KW  - safety
KW  - ABCB5
KW  - GMP
KW  - tumorigenicity
KW  - toxicity
KW  - persistence
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-240456
VL  - 21
ER  -